TBPH - Theravance Biopharma

-

$undefined

N/A

(N/A)

Theravance Biopharma NasdaqGM:TBPH Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes of medicines in the United States. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.

Location: 901 Gateway Boulevard, South San Francisco, CA, 94080, United States | Website: https://www.theravance.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

382.3M

Cash

130.9M

Avg Qtr Burn

N/A

Short % of Float

18.64%

Insider Ownership

4.54%

Institutional Own.

91.75%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

YUPELRI® (revefenacin) Details
Chronic obstructive pulmonary disease

Approved

Quarterly sales

TRELEGY ELLIPTA Details
Chronic obstructive pulmonary disease (COPD)

Approved

Quarterly sales

Ampreloxetine (TD-9855) Details
Multiple System Atrophy, Neurogenic orthostatic hypotension

Phase 3

Data readout

Failed

Discontinued

Izencitinib (TD-1473) (GUT-SELECTIVE JAK INHIBITOR) Details
Inflammatory bowel disease, Inflammatory disease, Ulcerative colitis, Crohns disease

Failed

Discontinued

Failed

Discontinued